Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Head and neck cancer; Renal cell carcinoma; Skin cancer; Urogenital cancer
- Focus Therapeutic Use
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.
- 03 May 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
- 09 Jan 2017 New trial record